Effect of maceligan on the systemic exposure of paclitaxel: In vitro and in vivo evaluation

European Journal of Pharmaceutical Sciences

Volumn 41, Issue 2, 2010, Pages 226-231

  Qiang, Fu ^a   Lee, Beom Jin ^b   Ha, Ilho ^c   Kang, Keon Wook ^a   Woo, Eun Rhan ^a   Han, Hyo Kyung ^a  

^a Chosun University   (South Korea)

^b Kangwon National University   (South Korea)

^c Inje University   (South Korea)

Author keywords

Bioavailability; Cellular uptake; Macelignan; P glycoprotein; Paclitaxel

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 3A4; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MACELIGNAN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NUTMEG; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BLOTTING, WESTERN; CYTOCHROME P-450 CYP3A; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HUMANS; LIGNANS; MICROSOMES, LIVER; PACLITAXEL; RATS;

EID: 77955845684     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.06.009     Document Type: Article

References (31)

1. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., Kumar G., McLeod J., Obach R.S., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J.T., Tweedie D., Vega J.M., Walsh J., Wrighton S.A. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 2003, 31:815-832.
2. Choi B.C., Choi J.S., Han H.K. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int. J. Pharm. 2006, 323:81-85.
3. Chung J.Y., Choo J.H., Lee M.H., Hwang J.K. Anticariogenic activity of macelignan isolated from Myristica fragrans (nutmeg) against Streptococcus mutans. Phytomedicine 2006, 13:261-266.
4. Cresteil T., Monsarrat B., Alvinerie P., Tréluyer J.M., Vieira I., Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res. 1994, 54:386-392.
5. Crosasso P., Ceruti M., Brusa P., Arpicco S., Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Control. Rel. 2000, 63:19-30.
6. Harris J.W., Rahman A., Kim B.R., Guengerich F.P., Collins J.M. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 1994, 54:4026-4035.
7. Huisman M.T., Chhatta A.A., van Tellingen O., Beijnen J.H., Schinkel A.H. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int. J. Cancer 2005, 116:824-829.
8. Im Y.B., Ha I., Kang K.W., Lee M.Y., Han H.K. Macelignan: a new modulator of P-glycoprotein in multidrug-resistant cancer cells. Nutr. Cancer 2009, 61:538-543.
9. Jin D.Q., Lim C.S., Hwang J.K., Ha I., Han J.S. Anti-oxidant and anti-inflammatory activities of macelignan in murine hippocampal cell line and primary culture of rat microglial cells. Biochem. Biophys. Res. Commun. 2005, 331:1264-1269.
10. Jin M.J., Seo K., Ha I., Han H.K. Determination of macelignan in rat plasma by high-performance liquid chromatography with ultraviolet detection. Arch. Pharm. Res. 2008, 31:945-949.
11. Kimura Y., Aoki J., Kohno M., Ooka H., Tsuruo T., Nakanishi O. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother. Pharmacol. 2002, 49:322-328.
12. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol. Chem. 1981, 256:10435-10441.
13. Lee J.T., Steelman L.S., McCubrey J.A. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004, 64:8397-8404.
14. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8:411-424.
15. Liscovitch M., Ravid D. A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett. 2007, 245:350-352.
16. Lundberg B.B. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J. Pharm. Pharmacol. 1997, 49:16-21.
17. McGuire W.P., Rowinsky E.K., Rosenheim N.B., Grumbine F.C., Ettinger D.S., Armstrong D.K. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasm. Ann. Intern. Med. 1989, 111:273-279.
18. Monsarrat B., Chatelut E., Royer I., Alvinerie P., Dubois J., Dezeuse A., Roche H., Cros S., Wright M., Canal P. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab. Dispos. 1998, 26:229-233.
19. Onyuksel H.A., Ramakrishnan S., Chai H.B., Pezzuto J.M. A mixed micellar formulation suitable for the parenteral administration of taxol. Pharm. Res. 1994, 11:206-212.
20. Panchagnula R. Pharmaceutical aspects of paclitaxel. Int. J. Pharm. 1998, 172:1-15.
21. Park B.Y., Min B.S., Kwon O.K., Oh S.R., Ahn K.S., Kim T.J., Kim D.Y., Bae K., Lee H.K. Increase of caspase-3 activity by lignans from Machilus thunbergii in HL-60 cells. Biol. Pharm. Bull. 2004, 27:1305-1307.
22. Sadhu S.K., Okuyama E., Fujimoto H., Ishibashi M. Separation of Leucas aspera, a medicinal plant of Bangladesh, guided by prostaglandin inhibitory and antioxidant activities. Chem. Pharm. Bull. (Tokyo) 2003, 51:595-598.
23. Sonnichsen D.S., Liu Q., Schuetz E.G., Schuetz J.D., Pappo A., Relling M.V. Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther. 1995, 275:566-575.
24. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Bejinen J.W., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 1997, 4:2031-2035.
25. Spratlin J., Sawyer M.B. Pharmacogenetics of paclitaxel metabolism. Crit. Rev. Oncol. Hematol. 2007, 61:222-229.
26. van Asperen J., van Tellingen O., van der Valk M.A., Rozenhart M., Beijnen J.H. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin. Cancer Res. 1984, 4:2293-2297.
27. Varma M.V., Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 2005, 25:445-453.
28. Wang Y.M., Sato H., Adachi I., Horikoshi I. Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of novel anticancer agent, taxol. Chem. Pharm. Bull. (Tokyo) 1996, 44:1935-1940.
29. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93:2325-2327.
30. Woo J.S., Lee C.H., Shim C.K., Hwang S.J. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm. Res. 2003, 20:24-30.
31. Zhang S., Yang X., Morris M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 2004, 65:1208-1216.